Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma

Brentuximab vedotin induces an overall response rate of 75% in patients with relapsed/refractory Hodgkin lymphoma, but its impact on future allogeneic transplantation (allo-HCT) is not known. We retrospectively examined the records of 18 patients with relapsed/refractory Hodgkin lymphoma who were tr...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Chen, Robert, Palmer, Joycelynne M., Thomas, Sandra H., Tsai, Ni-Chun, Farol, Len, Nademanee, Auayporn, Forman, Stephen J., Gopal, Ajay K.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2012
Gaiak:
Clinical Trials and Observations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3383201/
https://ncbi.nlm.nih.gov/pubmed/22611160
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-03-418673
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak